Home›ENT (Otolaryngology)› High tumoral PD-L1 expression correlates with increased local invasion and distant metastases in differentiated thyroid cancer
High tumoral PD-L1 expression correlates with increased local invasion and distant metastases in differentiated thyroid cancerHigh PD-L1 levels linked to thyroid cancer spread
Journal of investigative medicine : the official publication of the American Federation for Clinical ResearchPublished August 23, 2026Study authors: Mediratta Rajan K, Bernstein Ilia, Zheng Cheng, Schmidt Cindy, Ganti Apar Kishor, Band Hamid, Bennet…PubMed ↗DOI ↗Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that high tumoral PD-L1 expression is associated with increased risk of lymphovascular invasion and metastasis in DTC.
This meta-analysis synthesized data from 12 retrospective studies to evaluate the association between tumoral PD-L1 expression and clinical features in patients with differentiated thyroid cancer (DTC). The analysis focused on markers of tumor progression, including local invasion and metastatic potential.
Key findings indicate that high tumoral PD-L1 expression is significantly associated with lymphovascular invasion (OR 4.2; 95% CI 1.7-10.5), extrathyroidal extension (OR 1.7; 95% CI 1.2-2.4; p=0.005), and distant metastases (OR 4.6; 95% CI 1.6-13.0; p=0.004). These results suggest that PD-L1 overexpression may contribute to tumor progression via immune evasion pathways.
Conversely, the analysis found no significant association between PD-L1 status and several other clinical parameters, including tumor size, multifocality, lymph node metastasis, AJCC tumor stage, disease recurrence, or disease-specific mortality (p > 0.05). The authors note that all included studies were retrospective and of moderate quality.
Clinically, these findings suggest that PD-L1 expression may serve as a biomarker for identifying patients at higher risk for local invasion and distant metastasis in differentiated thyroid cancer. However, the observational nature of the data means these results represent associations rather than established causation.
How this fits prior evidence
This meta-analysis addresses a gap in understanding the role of immune evasion markers in differentiated thyroid cancer. While previous coverage noted that TSH suppression therapy promotes tumor progression via G-protein signaling pathways and that hemithyroidectomy is associated with a 3% higher risk difference in cancer recurrence rate, this study specifically links PD-L1 expression to local invasion (OR 4.2) and distant metastases (OR 4.6). It provides additional evidence regarding the biological mechanisms of progression beyond TSHR signaling.
Doctors are looking for better ways to understand how differentiated thyroid cancer behaves. A review of 12 past studies looked at a protein called PD-L1. This protein is often linked to how tumors hide from the immune system.
The analysis found that patients with high levels of this protein were much more likely to have certain complications. Specifically, these patients showed higher rates of lymphovascular invasion (where cancer cells enter blood or lymph vessels) and extrathyroidal extension (where the tumor grows outside the thyroid gland). The study also linked high PD-L1 levels to a higher risk of distant metastases, which means the cancer spread to other parts of the body.
It is important to note that while these links were clear, other factors like tumor size or how many tumors were present did not show a connection to the protein. Because the data came from retrospective studies of moderate quality, these findings are an important piece of the puzzle rather than a final word. Talk with your doctor about what these markers mean for specific treatment plans.
What this means for you:
High PD-L1 levels in thyroid cancer are linked to a higher risk of local and distant spread.
Common questions
What does a high PD-L1 level mean for thyroid cancer?
High levels of the PD-L1 protein are linked to a higher risk of the cancer spreading. Specifically, it is associated with lymphovascular invasion and growth outside the thyroid gland. It is also linked to a higher risk of distant metastases, which means the cancer moves to other parts of the body.
Does PD-L1 affect how large the tumor grows?
No, the study found no significant link between PD-L1 levels and factors like tumor size, how many tumors there are (multifocality), or the specific stage of the disease. These findings focus specifically on how the cancer spreads rather than its physical size.
Is this finding a guarantee of how my cancer will behave?
Not necessarily. The data comes from 12 retrospective studies of moderate quality. While it shows a strong link between PD-L1 and spread, it is an association rather than a guarantee. You should discuss these specific findings with your doctor to understand your personal risk.
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein that tumors exploit to evade T-cell-mediated surveillance. While PD-L1 overexpression has been linked to advanced disease and poor prognosis in many cancers, its clinicopathological significance in differentiated thyroid cancer (DTC) remains unclear. We conducted a systematic review and meta-analysis by searching MEDLINE, Embase, the Cochrane Library, and PubMed from inception to 2 January, 2023. Eligible studies reported PD-L1 immunohistochemical positivity in DTC and its correlation with clinicopathological features. Data were extracted in duplicate, and study quality was assessed with a modified Newcastle-Ottawa Scale (NOS). Pooled odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Heterogeneity was evaluated by the I value. Twelve retrospective studies met the inclusion criteria. All were retrospective and of moderate quality. High tumoral PD-L1 expression was significantly associated with the presence of lymphovascular invasion (LVI) (pooled OR 4.2, 95% CI 1.7-10.5), extrathyroidal extension (ETE) (pooled OR 1.7, 95% CI 1.2-2.4; = 0.005) and distant metastases (pooled OR 4.6, 95% CI 1.6-13.0; = 0.004). In other words, PD-L1-positive tumors were more likely to exhibit local invasion and distant metastasis. By contrast, PD-L1 status showed no significant association with tumor size, multifocality, lymph node metastasis, AJCC tumor stage, disease recurrence, or disease-specific mortality ( > 0.05 for all). Between-study heterogeneity was not significant for our key outcomes. PD-L1 overexpression in DTC is associated with a higher risk of local invasion and distant metastases, suggesting that PD-L1 may contribute to tumor progression via immune evasion.
